S&P 500 Index Posts a 13.4% Gain in 2012 — The Largest Since 2009

The Paragon Report Provides Stock Research on Caterpillar and Halliburton

Continue Reading

S&P 500 Index Posts Best Year Since 2009 — Bristol Myers Squibb and Johnson & Johnson Receive FDA Approvals

The Paragon Report Provides Stock Research on Bristol Myers Squibb and Johnson & Johnson

Continue Reading

China-s Sets First Round of 2013 Rare Earth Exports 27% Below 2012

Five Star Equities Provides Stock Research on Molycorp and Lynas

Continue Reading

Rare Industry Continues to Struggle With Low Prices and New Supplies — China Sets 2013 Rare Earth Exports Quotas

Five Star Equities Provides Stock Research on Rare Element Resources and Quest Rare Minerals

Continue Reading

Higher Rate of FDA New Drug Approvals a Major Factor in Biotech Industry-s Success in 2012

Five Star Equities Provides Stock Research on Progenics Pharmaceuticals and Vical

Continue Reading

Biotech Industry Skyrockets in 2012 as FDA New Drug Approval Rate Increases

Five Star Equities Provides Stock Research on Incyte and Oncolytics Biotech

Continue Reading

Oil & Gas Industry Struggles to Maintain Momentum in 2012 as Low Demand Continues to Pressure Prices

The Paragon Report Provides Stock Research on Denbury Resources and Dejour Energy

Continue Reading

Natural Gas Stocks in a Slump as Prices for the Commodity Fall Sharply on Lower Heating Demand

The Paragon Report Provides Stock Research on Exxon Mobil and Ultra Petroleum

Continue Reading

Oil and Gas Continues to Battle Slowing Demand — U.S. Oil Demand Falls to a 17-Year Low in October

The Paragon Report Provides Stock Research on Ivanhoe Energy and Talisman Energy

Continue Reading

Special Dividend Payments Surge in 2012 as Companies Look to Avoid Upcoming Dividend Tax Increase

Five Star Equities Provides Stock Research on CVS Caremark and Walgreen

Continue Reading